STOCK TITAN

Jasper Therapeutics Inc - JSPR STOCK NEWS

Welcome to our dedicated news page for Jasper Therapeutics (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jasper Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jasper Therapeutics's position in the market.

Rhea-AI Summary
Jasper Therapeutics, Inc. (JSPR) will present at the Oppenheimer 34th Annual Healthcare Conference to discuss the development of briquilimab, an antibody therapy targeting c-Kit to address various diseases. The presentation will be available via live webcast and archived replay on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18%
Tags
conferences
-
Rhea-AI Summary
Jasper Therapeutics, Inc. announced the pricing of its underwritten offering of 3,900,000 shares of its common stock at an offering price of $12.95 per share, generating gross proceeds of approximately $50 million. The net proceeds will be used for the advancement of preclinical and clinical development programs of briquilimab in mast-cell driven diseases and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.52%
Tags
offering
-
Rhea-AI Summary
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the presentation of preclinical data on briquilimab, a novel antibody therapy, at the AAAAI 2024 Annual Meeting. The data suggests the potential of briquilimab in treating mast cell driven diseases and allergic reactions in mice expressing chimeric human and mouse CD117. The company presented two poster presentations and an oral presentation, showcasing the therapeutic potential of briquilimab in preventing anaphylaxis and allergic asthma in mice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.65%
Tags
clinical trial
Rhea-AI Summary
Jasper Therapeutics, Inc. announced that three new employees were awarded grants of options to purchase an aggregate of 12,000 shares of voting common stock. Each option was granted pursuant to the company's Amended and Restated 2022 Inducement Equity Incentive Plan and will vest over four years. The exercise price of each option is $11.78. This announcement is in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary
Jasper Therapeutics, Inc. (Nasdaq: JSPR) has obtained EU Clinical Trials authorization for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively. The company expects to commence patient enrollment in the SPOTLIGHT study in the first quarter of 2024, with initial data readout in the second half of 2024. Initial data from the BEACON study is expected in mid-2024. Jasper Therapeutics also outlined its corporate priorities and anticipated milestones for 2024, including the initiation of Phase 1b/2a trials and key leadership appointments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
Rhea-AI Summary
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announces a 1-for-10 reverse stock split of its issued and outstanding voting common stock, reducing the number of shares from approximately 111.6 million to approximately 11.2 million. The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
762.61%
Tags
none
Rhea-AI Summary
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the grant of options to purchase 240,000 shares of common stock to three new employees. Each option has an exercise price of $0.49 and will vest over four years, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.17%
Tags
none
-
Rhea-AI Summary
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation (Flu/TBI) conditioning in older adults with acute myeloid leukemia (AML) in complete remission (CR) or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). The study demonstrated that a regimen of briquilimab plus Flu/TBI led to successful engraftment of donor blood stem cells without toxicities and promising early minimum residual disease clearance. Additionally, new positive results from the investigator-sponsored Phase 1b/2a study evaluating briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA) were presented at ASH, showing that briquilimab infusion appears to be safe and well tolerated in patients with FA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the dosing of the first patient in the phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of chronic spontaneous urticaria (CSU) called BEACON. The study aims to evaluate the safety, tolerability, and efficacy of briquilimab in adult CSU patients who remain symptomatic after treatment with, or who cannot tolerate, omalizumab. Jasper anticipates reporting preliminary data from the BEACON study in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
clinical trial
Rhea-AI Summary
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced FDA clearance of its IND application for a Phase 1b/2a clinical study evaluating subcutaneous briquilimab in the treatment of CSU. The company also provided a business update and reported Q3 2023 financial results, including a net loss of $17.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.1%
Tags
earnings
Jasper Therapeutics Inc

Nasdaq:JSPR

JSPR Rankings

JSPR Stock Data

292.72M
7.55M
6.15%
55.63%
2.48%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Redwood City

About JSPR

jasper therapeutics is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. jasper’s lead compound, jsp191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.